Bristol-Myers Squibb Company
General ticker "BMY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $103.6B (TTM average)
Bristol-Myers Squibb Company does not follow the US Stock Market performance with the rate: -8.3%.
Estimated limits based on current volatility of 1.3%: low 55.63$, high 57.12$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-01-02, amount 0.63$ (Y4.56%)
- Total employees count: 34100 (0.0%) as of 2024
- US accounted for 70.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Pricing pressures, Regulatory and compliance, Third-party risks, Pipeline and product risks, Liquidity and credit risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [49.84$, 72.72$]
- 2025-12-31 to 2026-12-31 estimated range: [56.29$, 80.85$]
Financial Metrics affecting the BMY estimates:
- Negative: with PPE of 50.1 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 20 > 18.33
- Positive: Operating cash flow per share per price, % of 13.12 > 12.91
- Negative: negative Net income
- Positive: Industry earnings per price (median), % of 5.62 > 4.45
- Positive: Industry operating profit margin (median), % of 20 > 9.53
- Positive: 5.42 < Industry operating cash flow per share per price (median), % of 7.82
- Positive: Interest expense per share per price, % of 1.68 <= 3.31
- Positive: Industry inventory ratio change (median), % of -0.49 <= -0.18
Short-term BMY quotes
Relationship graph
Long-term BMY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $46,159.00MM | $45,006.00MM | $48,300.00MM |
| Operating Expenses | $36,888.00MM | $36,534.00MM | $38,642.00MM |
| Operating Income | $9,271.00MM | $8,472.00MM | $9,658.00MM |
| Non-Operating Income | $-1,558.00MM | $-32.00MM | $-18,037.00MM |
| Interest Expense | $1,232.00MM | $1,166.00MM | $1,947.00MM |
| R&D Expense | $9,411.00MM | $9,207.00MM | $9,782.00MM |
| Income(Loss) | $7,713.00MM | $8,440.00MM | $-8,379.00MM |
| Taxes | $1,368.00MM | $400.00MM | $554.00MM |
| Profit(Loss)* | $6,327.00MM | $8,025.00MM | $-8,948.00MM |
| Stockholders Equity | $31,061.00MM | $29,430.00MM | $16,335.00MM |
| Inventory | $2,339.00MM | $2,662.00MM | $2,557.00MM |
| Assets | $96,820.00MM | $95,159.00MM | $92,603.00MM |
| Operating Cash Flow | $13,066.00MM | $13,860.00MM | $15,190.00MM |
| Capital expenditure | $1,118.00MM | $1,209.00MM | $1,248.00MM |
| Investing Cash Flow | $-1,062.00MM | $-2,295.00MM | $-21,352.00MM |
| Financing Cash Flow | $-16,962.00MM | $-9,416.00MM | $5,127.00MM |
| Earnings Per Share** | $2.97 | $3.88 | $-4.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.